Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

PURPOSE: Metastatic colorectal cancer (mCRC) is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumours driving varying prognosis. METHODS: Patients with KRAS/RAS-wild type (wt) mCRC treated in first line with epidermal growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Benavides, Manuel, Díaz-Rubio, Eduardo, Carrato, Alfredo, Abad, Albert, Guillén, Carmen, Garcia-Alfonso, Pilar, Gil, Silvia, Cano, María Teresa, Safont, María José, Gravalos, Cristina, Manzano, José Luis, Sánchez, Antonio, Alcaide, Julia, López, Rafael, Massutí, Bartomeu, Sastre, Javier, Martínez, Eva, Escudero, Pilar, Méndez, Miguel, Aranda, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890384/
https://www.ncbi.nlm.nih.gov/pubmed/31803504
http://dx.doi.org/10.1136/esmoopen-2019-000599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890384/
https://www.ncbi.nlm.nih.gov/pubmed/31803504
http://dx.doi.org/10.1136/esmoopen-2019-000599

Ejemplares similares